Dorfman Gary S, Lawrence Theodore S, Matrisian Lynn M
Weill Cornell Medical College, New York, New York, USA.
Clin Cancer Res. 2008 Sep 15;14(18):5700-6. doi: 10.1158/1078-0432.CCR-08-1263.
The interventive device pathway refers to one of six pathways developed by the Translational Research Working Group (TRWG) that, together, describe the core domains of early translational cancer research. This pathway focuses on the development of devices (as classified by the Food and Drug Administration), designed for local ablation of cancer or precancerous lesions (e.g., radiation therapy, microwave, radiofrequency ablation, and high-intensity focused ultrasound systems). This article describes the distinctive features of the pathway and issues that are encountered in the real-world development of interventive devices for the treatment of cancer. The interventive device pathway is envisioned to be a general guideline of the steps required for effective development, optimization, testing, and validation of developing devices, to be dynamic and adaptable, and to form a framework for discussions focused on improving the efficiency and effectiveness of new device development.
介入设备途径是转化研究工作组(TRWG)制定的六种途径之一,这六种途径共同描述了早期转化性癌症研究的核心领域。该途径专注于开发(按美国食品药品监督管理局分类)用于局部消融癌症或癌前病变的设备(例如放射治疗、微波、射频消融和高强度聚焦超声系统)。本文描述了该途径的独特特征以及在治疗癌症的介入设备实际开发过程中遇到的问题。介入设备途径被设想为开发设备进行有效开发、优化、测试和验证所需步骤的通用指南,具有动态性和适应性,并形成一个专注于提高新设备开发效率和有效性的讨论框架。